Fundz

Via Nova Therapeutics Announces $20 Million Series A Financing From Aditum Bio To Advance Four Antiviral Programs

PRIVATESep 07, 2021

Amount Raised

$20 Million

Round Type

Series A

Oakland

Description

Via Nova Therapeutics announced today that it has closed its Series A financing and raised $20 million from Aditum Bio to advance the development of four preclinical antiviral programs in-licensed from Novartis. The firm, founded by virologists Don Ganem, MD and Kelly Wong, PhD, was established to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs at Via Nova were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses and rhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The firm targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.

Who to call at Via Nova Therapeutics, and when

A new round usually means Via Nova Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Via Nova Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Via Nova Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Via Nova Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Via Nova Therapeutics

Location

Oakland, California, United States

About

The firm targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Via Nova Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Via Nova Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Via Nova Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.